Stocks and Investing
Stocks and Investing
Tue, November 15, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, November 14, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (ADCT) at Hold with Decreased Target to $7 on, Nov 14th, 2022
Matthew Harrison of Morgan Stanley, Maintained "ADC Therapeutics SA" (ADCT) at Hold with Decreased Target from $11 to $7 on, Nov 14th, 2022.
Matthew has made no other calls on ADCT in the last 4 months.
There are 4 other peers that have a rating on ADCT. Out of the 4 peers that are also analyzing ADCT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold and Decreased Target to $7 on, Wednesday, November 9th, 2022
These are the ratings of the 3 analyists that currently disagree with Matthew
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $20 on, Wednesday, November 9th, 2022
- Brian Cheng of "JP Morgan" Initiated at Buy and Held Target at $5 on, Wednesday, September 21st, 2022
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $21 on, Monday, September 19th, 2022
Contributing Sources